259 related articles for article (PubMed ID: 26090944)
1. Projected impact of Cervarix™ vaccination on oncogenic human papillomavirus infection and cervical cancer in the United Kingdom.
Van Effelterre TP; Hogea C; Taylor SM
Hum Vaccin Immunother; 2016; 12(1):8-19. PubMed ID: 26090944
[TBL] [Abstract][Full Text] [Related]
2. Projected impact of Cervarix® vaccination on oncogenic human papillomavirus infection and cervical cancer in the United Kingdom.
Van Effelterre T; Hogea C; Taylor S
Hum Vaccin Immunother; 2014; 10(7):1794. PubMed ID: 25424784
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
4. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
5. Cervical intraepithelial neoplasia grade 2 or worse in Galicia, Spain: HPV 16 prevalence and vaccination impact.
Pérez-Castro S; Lorenzo-Mahía Y; Iñarrea Fernández A; Lamas-González MJ; Sarán-Díez MT; Rubio-Alarcón J; Reboredo-Reboredo MC; Mosteiro-Lobato S; López-Miragaya I; Torres-Piñón J; Melón-García S
Enferm Infecc Microbiol Clin; 2014 Oct; 32(8):479-85. PubMed ID: 24274937
[TBL] [Abstract][Full Text] [Related]
6. UK population based study to predict impact of HPV vaccination.
Hibbitts S; Tristram A; Beer H; McRea J; Rose B; Hauke A; Nuttall D; Dallimore N; Newcombe RG; Fiander A
J Clin Virol; 2014 Feb; 59(2):109-14. PubMed ID: 24388208
[TBL] [Abstract][Full Text] [Related]
7. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
Drolet M; Bénard É; Pérez N; Brisson M;
Lancet; 2019 Aug; 394(10197):497-509. PubMed ID: 31255301
[TBL] [Abstract][Full Text] [Related]
8. Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation.
Mesher D; Cuschieri K; Hibbitts S; Jamison J; Sargent A; Pollock KG; Powell N; Wilson R; McCall F; Fiander A; Soldan K
J Clin Pathol; 2015 Feb; 68(2):135-40. PubMed ID: 25410654
[TBL] [Abstract][Full Text] [Related]
9. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.
Demarteau N; Tang CH; Chen HC; Chen CJ; Van Kriekinge G
Value Health; 2012; 15(5):622-31. PubMed ID: 22867770
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials.
Tota JE; Struyf F; Sampson JN; Gonzalez P; Ryser M; Herrero R; Schussler J; Karkada N; Rodriguez AC; Folschweiller N; Porras C; Schiffman M; Schiller JT; Quint W; Kreimer AR; Wheeler CM; Hildesheim A;
J Natl Cancer Inst; 2020 Aug; 112(8):818-828. PubMed ID: 31697384
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus types in cervical dysplasia among young HPV-vaccinated women: Population-based nested case-control study.
Kann H; Hortlund M; Eklund C; Dillner J; Faust H
Int J Cancer; 2020 May; 146(9):2539-2546. PubMed ID: 31868230
[TBL] [Abstract][Full Text] [Related]
13. Pre-vaccination type-specific HPV prevalence in confirmed cervical high grade lesions in the Māori and non-Māori populations in New Zealand.
Kang YJ; Lewis H; Smith MA; Simonella L; Neal H; Bromhead C; Canfell K
BMC Infect Dis; 2015 Aug; 15():365. PubMed ID: 26297490
[TBL] [Abstract][Full Text] [Related]
14. Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen-detected cervical precancer.
Inturrisi F; Lissenberg-Witte BI; Veldhuijzen NJ; Bogaards JA; Ronco G; Meijer CJLM; Berkhof J
Int J Cancer; 2021 Jan; 148(2):320-328. PubMed ID: 32663316
[TBL] [Abstract][Full Text] [Related]
15. HPV infections and cytologic abnormalities in vaccinated women 21-34 years of age: Results from the baseline phase of the Onclarity trial.
Wright TC; Parvu V; Stoler MH; Kodsi S; Eckert K; Yanson K; Cooper CK
Gynecol Oncol; 2019 May; 153(2):259-265. PubMed ID: 30853359
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus in invasive cervical cancer and cervical intraepithelial neoplasia 2 and 3 in Venezuela: a cross-sectional study.
Sánchez-Lander J; Cortiñas P; Loureiro CL; Pujol FH; Medina F; Capote-Negrín L; Bianchi G; García-Barriola V; Ruiz-Benni A; Avilán-Rovira J; Acosta H
Cancer Epidemiol; 2012 Oct; 36(5):e284-7. PubMed ID: 22608058
[TBL] [Abstract][Full Text] [Related]
17. Distribution of Human Papillomavirus (HPV) Genotypes in HIV-Negative and HIV-Positive Women with Cervical Intraepithelial Lesions in the Eastern Cape Province, South Africa.
Taku O; Mbulawa ZZA; Phohlo K; Garcia-Jardon M; Businge CB; Williamson AL
Viruses; 2021 Feb; 13(2):. PubMed ID: 33670231
[TBL] [Abstract][Full Text] [Related]
18. Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.
Song F; Yan P; Huang X; Wang C; Du H; Qu X; Wu R
BMC Cancer; 2022 Jan; 22(1):42. PubMed ID: 34991494
[TBL] [Abstract][Full Text] [Related]
19. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.
Van Kriekinge G; Castellsagué X; Cibula D; Demarteau N
Vaccine; 2014 Feb; 32(6):733-9. PubMed ID: 24291200
[TBL] [Abstract][Full Text] [Related]
20. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
